Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vintafolide + PLD in Platinum-Resistant Ovarian Cancer
NCT01170650Phase 3Terminated
- Sponsor
- Endocyte
- Start
- Apr 2011
- Primary completion
- May 2015
- Modality
- Prodrugs/Conditional Activator Small Molecules, Peptide-Drug Conjugates
01
Overview
A Phase 3 trial of vintafolide in ovarian cancer, sponsored by Endocyte. Started Apr 2011; status: terminated.
02
Drugs
vintafolide
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01170650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01170650.